Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAMES PATRICK DUGAN

Allopathic & Osteopathic Physicians Internal Medicine Hematology

NPI
1326304353
CMS profile
429826
Location
WINSTON SALEM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$68,723.38

67 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAMES PATRICK DUGAN

NPI 1326304353 · CMS profile ID 429826

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology

WINSTON SALEM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1326304353?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAMES PATRICK DUGAN, NPI 1326304353, CMS profile ID 429826. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1326304353?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JAMES PATRICK DUGAN, NPI 1326304353, CMS profile ID 429826. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1326304353?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JAMES PATRICK DUGAN, NPI 1326304353, CMS profile ID 429826, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1326304353?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

67 matching records · $68,723.38 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 67 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–67 of 67.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $464.3104/20/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014709337 CMS
Karyopharm Therapeutics Inc. $56.2404/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056902013 CMS
E.R. Squibb & Sons, L.L.C. $25.1804/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014708945 CMS
E.R. Squibb & Sons, L.L.C. $1,140.0004/13/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014708963 CMS
AbbVie Inc. $3,850.0004/04/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996756555 CMS
AbbVie Inc. $660.2903/30/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996756541 CMS
AbbVie Inc. $1,122.5003/30/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996756545 CMS
AbbVie Inc. $125.9103/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996756551 CMS
SOBI, INC $1,850.0003/23/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038087269 CMS
Celgene Corporation $332.1203/22/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014708923 CMS
Celgene Corporation $164.8803/22/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014709621 CMS
Celgene Corporation $184.6903/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014708937 CMS
PFIZER INC. $109.7203/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049374537 CMS
Karyopharm Therapeutics Inc. $83.3603/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056902009 CMS
Rigel Pharmaceuticals, Inc. $80.9602/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033378833 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $656.2502/08/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993436755 CMS
AbbVie Inc. $550.0001/04/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996756537 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $746.28 8
PY2020 $9,020.45 9
PY2021 $13,477.10 15
PY2022 $25,774.71 29
PY2023 $68,723.38 67
PY2024 $47,408.43 51
PY2025 $35,306.03 42

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,090.48 3
PY2025 Principal investigator $1,683,014.98 59
PY2024 Principal investigator $1,447,806.67 45
PY2023 Recipient $69.03 1
PY2023 Principal investigator $236,538.91 45
PY2022 Principal investigator $117,368.28 20

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

62 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $18,000.00 11/17/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2ARearrangements or NPM1Mutations who are Ineligible for Intensive Chemotherapy No dispute reported 06/30/2026 1175432906
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,540,783.98 10/28/2025 Non-covered Recipient Entity
NOVANT HEALTH HEART VAS INSTITUTE
A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia No dispute reported 06/30/2026 1190312531
Principal investigator 1 Astellas Pharma Global Development $1,361.10 10/22/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184215
Principal investigator 1 Astellas Pharma Global Development $1,361.10 10/22/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184217
Principal investigator 1 Astellas Pharma Global Development $1,361.10 10/22/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184219
Principal investigator 1 Astellas Pharma Global Development $2,219.00 10/22/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184221
Principal investigator 1 ABBVIE INC. $1,875.00 10/20/2025 Covered Recipient Teaching Hospital
FORSYTH MEMORIAL HOSPITAL INC
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202411606
Recipient Novartis Pharmaceuticals Corporation $802.38 10/11/2025 Covered Recipient Physician Research Publication/ Writing Support No dispute reported 06/30/2026 1190291399
Principal investigator 1 Janssen Research & Development, LLC $500.00 09/22/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 1b Study of JNJ-75276617 in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations No dispute reported 06/30/2026 1175432932
Principal investigator 1 Janssen Research & Development, LLC $1,556.00 09/15/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 1b Study of JNJ-75276617 in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations No dispute reported 06/30/2026 1175432952
Principal investigator 1 Astellas Pharma Global Development $150.00 09/08/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184207
Principal investigator 1 Astellas Pharma Global Development $2,090.00 09/08/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184209
Principal investigator 1 Astellas Pharma Global Development $150.00 09/08/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184211
Principal investigator 1 Astellas Pharma Global Development $200.00 09/08/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184213
Recipient Novartis Pharmaceuticals Corporation $126.05 08/05/2025 Covered Recipient Physician CABL001AUS08 No dispute reported 06/30/2026 1190292526
Principal investigator 1 Astellas Pharma Global Development $792.00 07/30/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184205
Principal investigator 1 Astellas Pharma Global Development $765.00 06/30/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184193
Principal investigator 1 Astellas Pharma Global Development $109.00 06/30/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184195
Principal investigator 1 Astellas Pharma Global Development $285.00 06/30/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184197
Principal investigator 1 Astellas Pharma Global Development $1,020.00 06/30/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184199
Principal investigator 1 Astellas Pharma Global Development $2,550.00 06/30/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184201
Principal investigator 1 Astellas Pharma Global Development $400.00 06/18/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184191
Principal investigator 1 Astellas Pharma Global Development $300.00 06/18/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184203
Principal investigator 1 Janssen Research & Development, LLC $3,527.00 06/02/2025 Covered Recipient Teaching Hospital
Forsyth Memorial Hospital Inc
A Phase 1b Study of JNJ-75276617 in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations No dispute reported 06/30/2026 1175387335
Principal investigator 1 Astellas Pharma Global Development $1,001.00 05/26/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184187
Principal investigator 1 Astellas Pharma Global Development $3,953.30 05/26/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184189
Principal investigator 1 ABBVIE INC. $4,690.00 05/07/2025 Covered Recipient Teaching Hospital
FORSYTH MEMORIAL HOSPITAL INC
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202411602
Principal investigator 1 Astellas Pharma Global Development $1,361.10 04/30/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184131
Principal investigator 1 Astellas Pharma Global Development $1,281.80 04/30/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184133
Principal investigator 1 Astellas Pharma Global Development $1,281.80 04/30/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184135
Principal investigator 1 Astellas Pharma Global Development $1,281.80 04/30/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184137
Principal investigator 1 Astellas Pharma Global Development $2,440.10 04/30/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184139
Principal investigator 1 Astellas Pharma Global Development $1,281.80 04/30/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184141
Principal investigator 1 Astellas Pharma Global Development $1,784.90 04/30/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184143
Principal investigator 1 Astellas Pharma Global Development $2,002.00 04/30/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184145
Principal investigator 1 Astellas Pharma Global Development $1,739.40 04/30/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184147
Principal investigator 1 Janssen Research & Development, LLC $8,767.00 04/07/2025 Covered Recipient Teaching Hospital
Forsyth Memorial Hospital Inc
A Phase 1b Study of JNJ-75276617 in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations No dispute reported 06/30/2026 1175387355
Principal investigator 1 Janssen Research & Development, LLC $8,436.00 04/03/2025 Covered Recipient Teaching Hospital
Forsyth Memorial Hospital Inc
A Phase 1b Study of JNJ-75276617 in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations No dispute reported 06/30/2026 1175387347
Principal investigator 1 Astellas Pharma Global Development $2,095.60 03/21/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184149
Principal investigator 1 Astellas Pharma Global Development $1,784.90 03/21/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184151
Principal investigator 1 Astellas Pharma Global Development $1,783.60 03/21/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184153
Principal investigator 1 Astellas Pharma Global Development $2,449.20 03/21/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184155
Principal investigator 1 Astellas Pharma Global Development $1,765.40 03/21/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184157
Principal investigator 1 Astellas Pharma Global Development $1,784.90 03/21/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184159
Principal investigator 1 Astellas Pharma Global Development $1,976.00 03/21/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184161
Principal investigator 1 Astellas Pharma Global Development $1,784.90 03/21/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184163
Principal investigator 1 Astellas Pharma Global Development $1,784.90 03/21/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184165
Principal investigator 1 Astellas Pharma Global Development $1,976.00 03/21/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184167
Principal investigator 1 Astellas Pharma Global Development $1,976.00 03/21/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184169
Principal investigator 1 Astellas Pharma Global Development $1,784.90 03/21/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184171
Principal investigator 1 Astellas Pharma Global Development $1,784.90 03/21/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184173
Principal investigator 1 Astellas Pharma Global Development $1,784.90 03/21/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184175
Principal investigator 1 Astellas Pharma Global Development $1,784.90 03/21/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184177
Principal investigator 1 Astellas Pharma Global Development $1,784.90 03/21/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184179
Principal investigator 1 Astellas Pharma Global Development $1,784.90 03/21/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184181
Principal investigator 1 Astellas Pharma Global Development $1,784.90 03/21/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184183
Principal investigator 1 Astellas Pharma Global Development $1,976.00 03/21/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184185
Principal investigator 1 Janssen Research & Development, LLC $21,665.00 03/03/2025 Covered Recipient Teaching Hospital
Forsyth Memorial Hospital Inc
A Phase 1b Study of JNJ-75276617 in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations No dispute reported 06/30/2026 1175387378
Recipient Novartis Pharmaceuticals Corporation $162.05 01/28/2025 Covered Recipient Physician CABL001AUS08 No dispute reported 06/30/2026 1190292531
Principal investigator 1 Astellas Pharma Global Development $500.00 01/22/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184127
Principal investigator 1 Astellas Pharma Global Development $1,972.00 01/22/2025 Non-covered Recipient Entity
NOVANT MEDICAL GROUP INC
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234184129
Principal investigator 1 Janssen Research & Development, LLC $589.00 01/17/2025 Covered Recipient Teaching Hospital
Forsyth Memorial Hospital Inc
A Phase 1b Study of JNJ-75276617 in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations No dispute reported 06/30/2026 1175387309